Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis

Table 1 Inhibition of the incidence and mean score of CIA by treatment with AMD3100

Experiment number	Treatment^a	Cumulative incidence (%)		Score of arthritis (mean ± SEM)
		Start of treatment^b	End of treatment^c	All mice^d	Arthritic mice only^e
1	AMD3100	2/10 (20%)	3/10 (30%)^f	1.4 ± 0.9^f	4.7 ± 2.4
	Control	2/12 (17%)	9/12 (75%)	5.2 ± 0.9	6.2 ± 0.6
2	AMD3100	1/7 (14%)	2/7 (29%)	0.9 ± 0.6^f	3.0 ± 1.0
	Control	2/7 (29%)	5/7 (71%)	2.4 ± 0.8	3.4 ± 0.7
3	AMD3100	2/8 (25%)	2/8 (25%)^g	0.6 ± 0.5^g	2.5 ± 1.5
	Control	1/8 (13%)	7/8 (88%)	3.9 ± 1.4	4.3 ± 1.5

The table shows the results of three individual experiments. Male mice were immunized with collagen type II/complete Freund's adjuvant on day 0. ^aAt the day first symptoms appeared (day 27 in experiment 1 and 2, day 24 in experiment 3), mice were divided into two groups and were implanted with osmotic minipumps delivering AMD3100 at a constant rate of 600 μg/day or PBS in the control groups. Distribution of the mice between the two groups was done in a way that an equal incidence and a similar clinical score was reached in both groups. ^bArthritic incidence in both groups at the start of the treatment is shown. ^cAt the end of the treatment, there was a significant inhibition of the incidence in the AMD3100-treated group compared to the control in experiments 1 and 3 (^fp < 0.05 and ^gp < 0.01, respectively; binomial proportion test). ^dAt the end of the treatment, the mean arthritic scores calculated for all mice were significantly different between the AMD3100-treated and control groups for all the three experiments (^fp < 0.05 for experiments 1 and 2; ^gp < 0.01 for experiment 3; Mann-Whitney U-test). ^eAt the end of the treatment, the mean arthritic scores calculated for mice with symptoms of arthritis were not significantly different between the AMD3100-treated and control groups. SEM, standard error of the mean.

ISSN: 1478-6362